webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Chemically Cleavable Linker

Chemically cleavable linkers are key structural units in the design of Antibody-Drug Conjugates (ADCs). They are responsible for precisely connecting cytotoxic payloads to antibodies via controllable chemical bonds, enabling drug release under specific chemical conditions. With predictable chemical cleavage mechanisms, these linkers play a central role in regulating drug release rates, optimizing plasma stability, and ensuring precise delivery within tumor cells. Leveraging years of experience in antibody conjugation and linker development, BOC Sciences offers a one-stop customized service—from linker design, synthesis, modification, and optimization to quality analysis—meeting diverse ADC development needs across different targets, pharmacodynamics, and release mechanisms.

What Are Chemically Cleavable Linkers?

Chemically cleavable linkers are linker structures that break in response to chemical reactions. Typically, these linkers contain chemical bonds sensitive to specific chemical stimuli such as changes in pH, reducing environments, oxidative conditions, or particular reagents. Upon reaching the target site, the linker undergoes hydrolysis, reduction, oxidation, or rearrangement triggered by the local chemical environment, releasing the active drug molecules. Unlike enzyme-cleavable linkers, chemically cleavable linkers rely on differences in the chemical microenvironment of tumors or lesions (e.g., pH, redox status, reactive oxygen species levels) to achieve site-specific drug release.

Fig. 1. Chemical-sensitive linker in ADC (BOC Sciences Authorized).

Chemically labile linkers are widely used in ADC clinical pipelines, with acid-sensitive linkers (such as hydrazones and silyl ethers) and disulfide linkers leading the field. Hydrazones are easily synthesized and exhibit a plasma half-life of 183 hours at pH 7 or 4.4 hours at pH 5, indicating selective cleavage under acidic conditions like those in lysosomes. The first-generation ADC gemtuzumab ozogamicin (Mylotarg) incorporates a hydrazone linker critical for drug potency. However, acidic conditions also exist in various bodily fluids, raising concerns of nonspecific drug release. Disulfide linkers exploit the reducing environment inside cells to release drugs in lysosomes following internalization and antibody degradation. Most disulfide-linked drugs are initially freed intact through proteolytic cleavage of the antibody and subsequently released as active metabolites via disulfide exchange or reduction by agents such as glutathione. The methylated drug metabolites can then diffuse through lipid membranes to reach their site of action.

What Chemically Cleavable Linker Options Do We Provide?

BOC Sciences possesses a rich chemical linker structure database and a mature synthesis platform, providing a wide range of classical and novel chemically cleavable linkers for ADC development. These cover various mechanisms including acid-sensitive, reduction-sensitive, and oxidative stress-sensitive types, matching different pharmacodynamic requirements and drug chemical properties. Common linkers we offer include:

Acid-Cleavable Linkers

Acid-cleavable linkers (pH-sensitive linkers) utilize the acidic intracellular tumor environment (pH 4.5–6.5) contrasted with the neutral blood environment to rapidly hydrolyze and release drugs under acidic conditions. BOC Sciences selects appropriate chemical structures such as hydrazone, acyl hydrazone, or acetal linkages based on the drug's structure, optimizing linker length and hydrophobicity to ensure stability in circulation and efficient release at the target site.

Reduction-Cleavable Linkers (Disulfide Linker)

Reduction-sensitive linkers depend on the high concentration of glutathione (GSH) within tumor cells to trigger disulfide bond cleavage and drug release. BOC Sciences specializes in customizing disulfide bond structures and protective groups tailored to drug properties, employing in vitro and in vivo reductive environment simulation platforms to test stability and cleavage rates, guaranteeing precise response to cytosolic reducing conditions.

ROS-Responsive Linkers

Oxidation-sensitive linkers leverage elevated reactive oxygen species (ROS) levels in tumor and inflammatory sites, utilizing boronate esters, thioethers, or selenoethers that cleave under oxidative conditions to release drugs. BOC Sciences screens ROS-sensitive chemical structures compatible with the drug and adjusts their activation thresholds to balance site-specific release and blood stability.

β-Elimination Linkers

β-Elimination linkers release drugs via β-elimination reactions triggered under certain chemical conditions, with reaction rates tunable through chemical modifications. BOC Sciences uses high-throughput synthesis platforms to customize diverse β-elimination structures and combines kinetic testing to optimize stability and release performance, meeting precise control requirements on release timing and dosage.

Get A Quote

Chemically Cleavable Linker Design Services

With advanced chemical synthesis platforms and comprehensive analytical systems, BOC Sciences provides full-process chemically cleavable linker services including design, structural optimization, custom synthesis, and conjugation process development. We understand that linkers influence not only ADC drug release mechanisms and plasma stability but also directly impact clinical efficacy and safety. Therefore, we strictly control quality and reproducibility at every R&D stage to ensure clients receive linker products with stable performance, strong controllability, and tailored to project needs.

Linker Structure Design and Mechanism Screening

  • Precisely matching drug and target environment: Based on the chemical properties of the client's drug molecule (e.g., hydrophobicity, hydrophilicity, molecular weight, chemical stability) and the intracellular and extracellular environment of the target cells (pH, redox status, ionic concentration differences), we recommend the optimal chemically cleavable strategy.
  • Diverse cleavage mechanism options: Including acid-sensitive, reduction-sensitive, metal ion-sensitive, ROS-responsive, and development of dual-trigger hybrid linkers.
  • Pharmacokinetics and stability prediction: Using molecular modeling and simulation experiments to forecast linker stability and release profiles in plasma and target cells.

Custom Synthesis and Structural Modification

  • Full-scale synthesis capacity: From milligram-scale (laboratory research) to kilogram-scale (commercial production), meeting needs from early research to preclinical manufacturing.
  • Introduction of reactive groups: Functional groups such as maleimide, azide, alkyne, hydroxyl, and amine can be introduced at either end or specific linker positions, compatible with diverse conjugation strategies.
  • Solubility and hydrophobicity regulation: Adjusting linker water solubility and hydrophobicity via PEGylation, fluorination, and other modifications to improve conjugation efficiency and drug delivery performance.

Conjugation Process Development and DAR Control

  • Process parameter optimization: Systematic optimization of pH, temperature, solvent systems, and reaction time to enhance conjugation efficiency and stability.
  • Site-specific and random conjugation: Offering site-specific conjugation for uniform DAR distribution or random conjugation for rapid R&D, based on client requirements.
  • DAR (Drug-to-Antibody Ratio) control: Precise control of drug loading by adjusting linker length and number of reactive sites to optimize pharmacokinetics and toxicity balance.

Stability and Release Kinetics Evaluation

  • In vitro stability testing: Assessment of chemical stability in simulated plasma environment (pH 7.4) at human body temperature.
  • Release condition validation: Measuring drug release rate and efficiency under simulated tumor microenvironment conditions (low pH, high GSH, high ROS, or metal ion enrichment).
  • Long-term storage stability: Verification of degradation rates and chemical property changes under various storage conditions.

Why We Are Your Best Partner for Custom Linker Development?

01

Extensive ADC Linker Development Experience

BOC Sciences has years of experience in linker design, synthesis, and optimization, successfully supporting multiple ADC projects advancing to clinical stages, including acid-sensitive, reduction-sensitive, and hybrid mechanisms, ensuring mature and feasible solutions.

02

Highly Customized Design Capability

We tailor linker structures based on client drug structure, target characteristics, and release requirements—including length, spatial configuration, hydrophobicity/hydrophilicity, and reactive groups—to achieve optimal efficacy and stability balance.

03

One-Stop R&D and Manufacturing Platform

Providing full-process services from linker screening, custom synthesis, conjugation process development to quality control, covering milligram-scale research to kilogram-scale scale-up production, shortening ADC development timelines and reducing project risks.

04

Strict Quality and Regulatory Compliance

Manufacturing processes comply with cGMP and ISO quality systems, offering complete COA, SDS, and R&D documentation to ensure chemically cleavable linkers are directly applicable for preclinical and clinical research.

05

Efficient Delivery Timeline and Cost Optimization

Optimizing synthetic routes and reaction conditions to improve efficiency, shorten project turnaround, and reduce production costs, helping clients gain a time advantage in the competitive ADC market.

06

Global Service and Technical Support

Supported by an international team and advanced analytical platforms, we serve global clients' ADC linker customization needs and provide comprehensive technical support from project initiation to regulatory submission, ensuring smooth R&D progression.

Standardized Linker Development Service Workflow

Scheme Design and Contract Customization

Requirement Communication and Project Evaluation

Before project initiation, the BOC Sciences team engages in deep discussions with clients to thoroughly understand drug structure, target environment, expected release mechanisms, and project timelines. Leveraging professional experience and technical reserves, we assess project feasibility and technical challenges to lay a solid foundation for design.

Payload/Linker Synthesis

Solution Design and Technical Confirmation

Based on project requirements, we design multiple linker solutions compatible with chemical cleavage mechanisms. Combining molecular modeling and literature data, we screen for optimal structures. Clients participate in solution reviews to confirm design details, ensuring alignment with drug conjugation and efficacy requirements.

Scheme Design and Contract Customization

Linker Synthesis and Structural Validation

Entering laboratory phase, we conduct small-scale synthesis with strict reaction monitoring to guarantee linker purity and structural accuracy. Using NMR, LC-MS, and other analytical methods, we verify molecular structures and ensure product compliance with design criteria.

Analysis, Purification and Characterization

Process Scale-up and Conjugation Optimization

Based on small-scale results, we develop pilot and scale-up production processes. Concurrently, we optimize conjugation conditions with antibodies, adjusting reaction parameters to achieve ideal drug loading and conjugate stability.

cGMP Manufacturing and Filling

Stability Testing and Release Performance Evaluation

Conduct in vitro stability assessments on synthesized linkers and conjugates, including plasma stability and storage stability tests. Simulate tumor microenvironment to measure chemical cleavage rates, ensuring efficient and controllable drug release mechanisms.

Result Delivery

Quality Control and Project Delivery

Complete comprehensive quality control throughout the process, providing detailed analytical reports and Certificates of Analysis (COA). Project deliverables are ready for direct application in preclinical research or further development. BOC Sciences ensures clients receive high-quality products on schedule to meet R&D objectives.

Frequently Asked Questions

Frequently Asked Questions

Still have questions?

Contact Us

Case Study

Case Study 1 Custom Hydrazone Linker Enables Dual Breakthrough in Targeting and Stability for a Novel ADC

Background

A biopharmaceutical company was developing a novel ADC with a core requirement to design a chemically cleavable linker capable of specifically releasing cytotoxins inside tumor cells. Given the candidate ADC's cytotoxic payload demanded extremely high conjugation stability and controlled release, conventional enzyme-cleavable linkers could not meet the dual needs for precise release and plasma stability. The project urgently required innovative custom development of a hydrazone linker to ensure efficient targeting and safety.

How BOC Sciences Helped

Leveraging extensive ADC linker development experience, BOC Sciences collaborated closely with the client to deeply analyze the drug's structure and tumor microenvironment characteristics. Multiple acid-sensitive chemically cleavable linker schemes centered on hydrazone linkers were designed and screened. Molecular modeling predicted hydrazone linker cleavage kinetics under various pH conditions, optimizing structures to balance plasma stability and tumor-targeted release efficiency. Meanwhile, hydrazone linkers featuring multifunctional reactive groups were custom synthesized to ensure efficient conjugation and adaptability to downstream processing.

Implementation Process

  • Requirement analysis and design: Comprehensive understanding of the client's drug molecular structure, mechanism of action, and target environment, formulating preliminary hydrazone linker designs.
  • Small-scale synthesis and analytical verification: Multiple batches of small-scale hydrazone linker synthesis completed, with stringent structure and purity validation using NMR, LC-MS, and other technologies.
  • Conjugation process development: Optimization of conjugation conditions between hydrazone linkers and antibodies, adjusting reaction parameters to ensure stable and controllable DAR.
  • In vitro stability and release testing: Assessment of hydrazone linker stability in simulated plasma and tumor microenvironment, plus cleavage rates under acidic conditions to meet preclinical research standards.
  • Process scale-up and quality control: Advancement to pilot and kilogram-scale production, establishing strict quality control systems to ensure batch consistency and reliable supply.

Key Results

  • Successfully developed a hydrazone-based chemically cleavable linker combining high plasma stability with efficient intracellular drug release in tumor cells.
  • Achieved conjugate DAR meeting design targets with conjugation efficiency exceeding 90%.
  • In vitro cleavage tests showed drug release rates of the hydrazone linker at target pH notably superior to traditional enzyme-cleavable linkers.
  • Process scale-up ensured stable and consistent batch supply of hydrazone linkers, supporting the client's subsequent preclinical development milestones.

Publications

With exceptional quality and stable performance, BOC Sciences' ADC linker products and custom services have gained broad recognition from researchers worldwide and have been cited in multiple studies published in top international journals. These publications not only highlight BOC Sciences' technological expertise in the linker field but also underscore its significant role in driving innovative ADC drug development and fostering global academic collaboration.

Customer Testimonials

More About ADC Linkers

* Only for research. Not suitable for any diagnostic or therapeutic use.
Support Documents

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

Purity Guaranteed

≥95%
Purity Guaranteed

Countries/Regions Delivered

20+
Countries/Regions Delivered

Technical Support

24/7
Technical Support

Products In Stock

1,000+
Products In Stock

High-Quality Service

100%
High-Quality Service
Send Inquiry
Verification code
Inquiry Basket